PREVIOUS ISSUE NEXT ISSUE
January 2017 OT010117_Cover.jpg
Tracking treatment adherence in newly diagnosed open-angle glaucomaAn analysis of U.S. claims data reveals a substantial proportion of patients (17%) remained untreated 4 years after their initial diagnosis of open-angle glaucoma.
Poor oral health may be associated with POAGRecent tooth loss and periodontal disease have been linked to primary open-angle glaucoma in a large prospective study of male health professionals.
When an artist loses vision
Add-on module enhances diagnostic accuracy in glaucomaA new add-on glaucoma module has the capability of creating an anatomic map of each patient’s eye by using two fixed landmarks. The module also includes an extensive reference data base.
European study with microstent demonstrates lowered IOP, use of fewer drugsPatients with cataract surgery and microstent implantation had a lowered IOP and a reduced number of medications used at 3 years postoperatively
Cyclophotocoagulation device can help lower IOPConsider factors such as glaucoma severity, eye pigmentation, and medication use when selecting power settings for the MicroPulse P3 device.
Novel ocular hypotensive drug meets endpointsNetarsudil ophthalmic solution 0.02% met its primary and secondary efficacy endpoints in a third phase III trial investigating its non-inferiority to timolol maleate 0.05% for IOP lowering.
Laser system offers multiple treatments in single deviceNew laser technology in a single device offers multiple treatment platforms, including SLT for glaucoma, laser vitreolysis for floaters, capsulotomy, and iridotomy.
Exploring risk, reward in trabecular bypass, suprachoroidal devicesThough much focus for stents has been in the trabecular meshwork, many companies are currently developing suprachorodial devices, which are in various stages of FDA review.
Pain-preventing NSAID welcomed by patients and cliniciansA new 0.075% formulation of bromfenac ophthalmic solution (BromSite, Sun Pharma) could provide relief from pain and inflammation associated with cataract surgery.
Pelvic organ prolapse may be clue to presence of exfoliation syndrome
Intracameral prostaglandin analogue therapy delivers durable benefitFive patients receiving an extended-release travoprost delivery system (ENV515, Envisia Therapeutics) in the anterior chamber have ongoing IOP-lowering with follow-up to 9 months in an ongoing study.
Cyclosporine for dry eye associated with anti-PD-1 therapyTopical cyclosporine may be useful for treating dry eyes associated with immunomodulatory agents like nivolumab, which markedly upregulate T cell activation. In caring for patients with ocular side effects associated with cancer treatment, the delivery of proper ophthalmic care is critical.
PREVIOUS ISSUE NEXT ISSUE